Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)

Keros Therapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $16.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 23.15% year-over-year to $16.0 million; the TTM value through Dec 2025 reached $16.0 million, down 23.15%, while the annual FY2025 figure was $16.0 million, 23.15% down from the prior year.
  • Accumulated Expenses reached $16.0 million in Q4 2025 per KROS's latest filing, up from $15.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $22.2 million in Q3 2024 to a low of $5.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $12.6 million, with a median of $12.5 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 87.71% in 2021, then crashed 31.55% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $7.3 million in 2021, then soared by 73.77% to $12.8 million in 2022, then surged by 40.5% to $17.9 million in 2023, then rose by 16.48% to $20.9 million in 2024, then decreased by 23.15% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Accumulated Expenses are $16.0 million (Q4 2025), $15.2 million (Q3 2025), and $20.0 million (Q2 2025).